Fulcrum Therapeutics (FULC) Free Cash Flow (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Free Cash Flow of -$16.1 million for Q2 2026, down 16.29% year-over-year from -$19.3 million in Q2 2025, and up 13.92% quarter-over-quarter from -$18.8 million in Q1 2026.
Fulcrum Therapeutics (FULC) Free Cash Flow (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Free Cash Flow for 9 consecutive years, with -$16.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Free Cash Flow fell 16.29% year-over-year to -$16.1 million; the TTM figure through Jun 2026 stood at -$66.1 million (down 1.41% YoY), while the FY2025 annual figure was -$60.4 million, down 2319.03% from the prior year.
- Free Cash Flow advanced to -$16.1 million in Q2 2026 per FULC's latest filing, from -$18.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $58.9 million in Q2 2024 and bottomed at -$28.2 million in Q3 2022.
- Historically, Free Cash Flow has averaged -$16.0 million across 5 years, with a median of -$19.5 million in 2022.
- Annual changes were most pronounced in 2024 — Free Cash Flow jumped 380.74% — and 2025, when it sank 123.57%.
- Fulcrum Therapeutics' Free Cash Flow stood at -$19.8 million in 2022, then fell by 17.28% to -$23.2 million in 2023, then increased by 27.44% to -$16.9 million in 2024, then declined by 0.56% to -$17.0 million in 2025, then grew by 4.75% to -$16.1 million in 2026.
- Business Quant data shows FULC's Free Cash Flow at -$16.1 million in Q2 2026, -$18.8 million in Q1 2026, and -$17.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | -16.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.15 Mn |
| Jun 30, 2026 | -16.15 Mn |
| Mar 31, 2026 | -18.76 Mn |
| Mar 31, 2026 | -18.76 Mn |
| Dec 31, 2025 | -16.96 Mn |
| Dec 31, 2025 | -16.96 Mn |
| Sep 30, 2025 | -14.35 Mn |
| Sep 30, 2025 | -14.35 Mn |
| Jun 30, 2025 | -13.82 Mn |
| Jun 30, 2025 | -13.82 Mn |
| Mar 31, 2025 | -15.26 Mn |
| Mar 31, 2025 | -15.26 Mn |
| Dec 31, 2024 | -16.99 Mn |
| Dec 31, 2024 | -16.99 Mn |
| Sep 30, 2024 | -19.10 Mn |
| Sep 30, 2024 | -19.10 Mn |
| Jun 30, 2024 | 58.91 Mn |
| Jun 30, 2024 | 58.91 Mn |
| Mar 31, 2024 | -25.31 Mn |
| Mar 31, 2024 | -25.31 Mn |